SCHEMBL6423398

SCHEMBL6423398

CC(C)(C)c1ccc(CSc2ccc3c(c2)OCC(=O)N3)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.49
PARP1 P09874 1/20 0.45
DRD4 P21917 8/20 0.43
DRD3 P35462 8/20 0.43
DRD2 P14416 7/20 0.43
DAO P14920 1/20 0.42
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
HTR1A P08908 1/20 0.40
CHRM5 P08912 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
HTR2A P28223 1/20 0.40
ADRA1B P35368 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
KIF11 P52732 1/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
SCN5A Q14524 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427774 0.84 DRD4 (0.56) PARP1DRD4DRD3DRD2DAO
SCHEMBL6295838 0.84 PARP1 (0.45) PARP1DRD4DRD3DRD2ADRB2
SCHEMBL6297055 0.84 DRD2 (0.51) PARP1DRD4DRD3DRD2HTR1A
SCHEMBL6297054 0.84 DRD4 (0.58) PARP1DRD4DRD3DRD2DAO
SCHEMBL762348 0.79 TRPV1 (0.58) TRPV1PARP1DRD4DRD3DRD2
SCHEMBL24864966 0.74 TRPV1 (0.65) TRPV1KIF11MMP12
SCHEMBL30336331 0.74 TRPV1 (0.65) TRPV1KIF11MMP12
SCHEMBL19326979 0.73 PARP1 (0.55) PARP1DRD4DRD3DRD2HTR1A
SCHEMBL6295486 0.73 MAPT (0.38) PARP1DRD4DRD3DRD2HTR1A
SCHEMBL13676060 0.72 TRPV1 (0.66) TRPV1KIF11GRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951855-B2 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2005-10-04 US disclosed
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis HAX1, VEGFA, HYOU1 TRPV1 2029/4885PARP1 2666/4885DRD4 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.